| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/HUM.2014.092 |
| P8608 | Fatcat ID | release_k7uer3opovfrbaddtiwi6xsmhu |
| P932 | PMC publication ID | 4180303 |
| P698 | PubMed publication ID | 25141764 |
| P5875 | ResearchGate publication ID | 264990058 |
| P50 | author | Rob C Hoeben | Q47504188 |
| P2093 | author name string | Martine L M Lamfers | |
| Victor W van Beusechem | |||
| Zineb Belcaid | |||
| P2860 | cites work | Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells | Q44502787 |
| Oncolytic viruses as therapeutic cancer vaccines | Q21245758 | ||
| Adenosine deaminase: characterization and expression of a gene with a remarkable promoter | Q24555814 | ||
| Molecular mechanisms of T cell co-stimulation and co-inhibition | Q26864888 | ||
| PAMPs and DAMPs: signal 0s that spur autophagy and immunity | Q27004190 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| A new technique for the assay of infectivity of human adenovirus 5 DNA | Q27860797 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Autophagic cell death: the story of a misnomer | Q29614564 | ||
| Targeting tumor vasculature with an oncolytic virus | Q30500348 | ||
| Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity | Q33202718 | ||
| Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. | Q33262597 | ||
| An oncolytic adenovirus redirected with a tumor-specific T-cell receptor | Q33308470 | ||
| Directed evolution generates a novel oncolytic virus for the treatment of colon cancer | Q33344440 | ||
| Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial | Q33379689 | ||
| Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging | Q33641230 | ||
| The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity | Q33670728 | ||
| Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus | Q33690982 | ||
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy | Q33933665 | ||
| Anatomical differences determine distribution of adenovirus after convection-enhanced delivery to the rat brain | Q34055421 | ||
| Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma | Q34102273 | ||
| Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic | Q34103007 | ||
| Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo | Q34291201 | ||
| Conditionally replicating adenoviruses expressing short hairpin RNAs silence the expression of a target gene in cancer cells. | Q34313965 | ||
| Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells | Q44899739 | ||
| Who's afraid of replication-competent adenoviruses? | Q45102958 | ||
| Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells | Q45110054 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. | Q45856129 | ||
| Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements | Q45856304 | ||
| A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor. | Q45864653 | ||
| Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors | Q45869203 | ||
| Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells | Q45870684 | ||
| Bone marrow gene transfer in three patients with adenosine deaminase deficiency. | Q45879021 | ||
| Lymphocyte gene therapy | Q45881517 | ||
| Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody | Q45882951 | ||
| An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents | Q45885443 | ||
| Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus | Q45885739 | ||
| The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma | Q46364445 | ||
| Homing properties of adipose-derived stem cells to intracerebral glioma and the effects of adenovirus infection | Q48888957 | ||
| Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine | Q50064816 | ||
| Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity | Q57541531 | ||
| Adenovirus DNA replication | Q64378704 | ||
| Vitamin D3-inducible mesenchymal stem cell-based delivery of conditionally replicating adenoviruses effectively targets renal cell carcinoma and inhibits tumor growth | Q64379255 | ||
| Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma | Q72850896 | ||
| Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity | Q82067713 | ||
| Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma | Q84834335 | ||
| Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma | Q84906858 | ||
| Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1 | Q85435790 | ||
| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Q34327051 | ||
| Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. | Q34460916 | ||
| Immunosuppression promotes reovirus therapy of colorectal liver metastases | Q34502982 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial | Q34759406 | ||
| Directing systemic oncolytic viral delivery to tumors via carrier cells | Q35029126 | ||
| Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity | Q35076737 | ||
| Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity | Q35155049 | ||
| A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer | Q35678429 | ||
| Life after death: targeting high mobility group box 1 in emergent cancer therapies | Q36562901 | ||
| Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation | Q36673709 | ||
| Gene therapy in The Netherlands: highlights from the Low Countries | Q36920198 | ||
| Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic | Q36931431 | ||
| Trial watch: Oncolytic viruses for cancer therapy | Q37028023 | ||
| Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model | Q37141874 | ||
| Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells | Q37157961 | ||
| Cell death in the host response to infection | Q37195729 | ||
| Immunogenic cancer cell death: a key-lock paradigm | Q37198125 | ||
| Tumor infection by oncolytic reovirus primes adaptive antitumor immunity | Q37239555 | ||
| Coronavirus genetically redirected to the epidermal growth factor receptor exhibits effective antitumor activity against a malignant glioblastoma | Q37256658 | ||
| Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice | Q37330624 | ||
| Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor | Q37336713 | ||
| Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas | Q37461117 | ||
| Cytoplasmic functions of the tumour suppressor p53. | Q37466228 | ||
| Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. | Q37596543 | ||
| Innate immunity to adenovirus | Q37718852 | ||
| Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine | Q37899222 | ||
| Chapter four--Design of improved oncolytic adenoviruses | Q38047473 | ||
| Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies | Q38139255 | ||
| Evolution of oncolytic viruses: novel strategies for cancer treatment | Q38159802 | ||
| Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses. | Q38185772 | ||
| Imaging preclinical tumour models: improving translational power | Q38221430 | ||
| Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans | Q38450392 | ||
| Mammalian orthoreovirus T3D infects U-118 MG cell spheroids independent of junction adhesion molecule-A. | Q39003421 | ||
| Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer | Q39013607 | ||
| Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection | Q39037822 | ||
| Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures. | Q39116798 | ||
| Reovirus modulates autophagy during oncolysis of multiple myeloma | Q39209865 | ||
| Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus | Q39384127 | ||
| Measles virus causes immunogenic cell death in human melanoma. | Q39428453 | ||
| The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses | Q39455183 | ||
| A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction. | Q39455900 | ||
| Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming | Q39588655 | ||
| Directed adenovirus evolution using engineered mutator viral polymerases | Q39622784 | ||
| Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished | Q39682744 | ||
| The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. | Q39792514 | ||
| Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D. | Q39798367 | ||
| Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma | Q39874999 | ||
| Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. | Q39887869 | ||
| Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma | Q39889523 | ||
| Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. | Q39923110 | ||
| Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors | Q39957477 | ||
| A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting. | Q39957922 | ||
| Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. | Q40036993 | ||
| Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation | Q40056582 | ||
| Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death | Q40277603 | ||
| Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus | Q40284343 | ||
| Genetic targeting of adenovirus vectors using a reovirus sigma1-based attachment protein | Q40309058 | ||
| Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. | Q40360926 | ||
| Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. | Q40387611 | ||
| Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. | Q40454824 | ||
| Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma | Q40525035 | ||
| Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX | Q40579221 | ||
| Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. | Q40628834 | ||
| Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters | Q40810220 | ||
| Recombinant adenovirus vectors with knobless fibers for targeted gene transfer | Q40906930 | ||
| The Nogo receptor NgR1 mediates infection by mammalian reovirus. | Q42210794 | ||
| Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer | Q42236448 | ||
| Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma | Q42950209 | ||
| A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer | Q43666519 | ||
| Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma | Q43848150 | ||
| Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. | Q43933421 | ||
| Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. | Q44183106 | ||
| The organotypic multicellular spheroid is a relevant three-dimensional model to study adenovirus replication and penetration in human tumors in vitro | Q44200179 | ||
| P433 | issue | 10 | |
| P921 | main subject | oncolytic virus | Q1560099 |
| virology | Q7215 | ||
| P304 | page(s) | 875-884 | |
| P577 | publication date | 2014-09-17 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses | |
| P478 | volume | 25 |
| Q97543035 | Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy | cites work | P2860 |
Search more.